Absence of neurotoxicity of chronic L-DOPA in 6-hydroxydopamine lesioned rats

NeuroReport

Volumn 8, Issue 4, 1997, Pages 975-979

  Dziewczapolski, Gustavo ^a   Murer, Gustavo ^b   Agid, Yves ^b   Gershanik, Oscar S ^a   Raisman Vozari, Rita ^b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

6 Hydroxydopamine; L DOPA therapy; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

CARBIDOPA; LEBOCAR 250; LEVODOPA; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; IMMUNOHISTOCHEMISTRY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

EID: 0030901296     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199703030-00031     Document Type: Article

References (25)

1. Jellinger K. The pathology of parkinsonism. In: Marsden CD and Fahn S, eds. Movement Disorders, Vol. 2. London: Butterworths, 1987: 124-165.
2. Caraceni T, Scigliano G and Musicco M. Neurology 41, 380-384 (1991).
3. Mena MA, Pardo B, Paino CN et al. NeuroReport 4, 438-440 (1993).
4. Pardo B, Mena MA, Fahn S et al. Movement Disord 8, 268-273 (1993).
5. Mytilineou C, Han S-K and Cohen G. J Neurochem 61, 1470-1478 (1993).
6. Steece-Collier K, Collier TJ, Sladek CD et al. Exp Neurol 110, 201-208 (1990).
7. Diamond SG, Markhman CH, Hoehn MM et al. Ann Neurol 22, 8-12 (1987).
8. Blin J, Bonnet A and Agid Y. Neurology 38, 1410-1416 (1988).
9. Cedarbaum JM, Gandy SE and McDowell FH. Neurology 41, 622-629 (1991).
10. Hefti F, Melamed E, Bhawan J et al. Neurology 31, 1194-1195 (1981).
11. Perry TL, Wee Yong V, Ito M et al. J Neurochem 43, 990-993 (1984).
12. Quinn N, Parker D, Janota I et al. Movement Disord 1, 65-68 (1986).
13. Agid Y, Javoy F and Glowinski J. Nature 245, 150-151 (1973).
14. Blunt SB, Jenner P and Marsden CD. Movement Disord 8, 129-133 (1993).
15. Blanchard V, Chritin M, Vyas S et al. J Neurochem 64, 1669-1679 (1995).
16. Paxinos G and Watson C. The Rat Brain in Stereotoxic Coordinates. New York: Academic Press, 1986.
17. Hefti F, Melamed E and Wurtman RJ. Brain Res 195, 123-137 (1980).
18. Han S-K, Mytilineou C and Cohen G. J Neurochem 66, 501-510 (1996).
19. Uitti RJ, Ahlskog JE, Maraganore DM et al. Neurology 43, 1918-1926 (1993).
20. Graham DG. Mol Pharmacol 14, 633-643 (1978).
21. Hastings TG, Lewis Da and Zigmond MJ. Proc Natl Acad Sci USA 93, 1956-1961 (1996).
22. Ceccatelli S, Ernfors P, Villar MJ et al. Proc Natl Acad Sci USA 88, 10352-10356 (1991).
23. Blanchard V, Anglade P, Dziewczpolski G et al. Brain Res 709, 319-325 (1996).
24. Colpaert FC. Noradrenergic mechanisms in Parkinson's disease: a theory. In: Briley M and Marien M, eds. Noradrenergic Mechanisms in Parkinson's Disease. Boca Raton: CRC Press, 1994: 225-254.
25. Mena MA, Bogulavsky J, Ryjak I et al. Soc Neurosci Abstr 22, 533 (1996).